Pubblicazioni Dr Armando Santoro 2013 Agg 19 sett 2013

Dott. Armando Santoro
Elenco Pubblicazioni e Comunicazioni Scientifiche
ARTICOLI ORIGINALI - 2013
A1.
G. Ceresoli, P. Zucali, M. Mencoboni, M. Botta, F. Grossi, D. Cortinovis, N.
Zilembo, C. Ripa, M. Tiseo, A. Favaretto, H. Soto Parra, F. de Vincenzo, A.
Bruzzone, E. Lorenzi, L. Gianoncelli, B. Ercoli, L. Giordano, A. Santoro: Phase II
study of Pemetrexed and Carboplatin plus Bevacizumab
as first-line therapy in malignant pleural mesothelioma.
British Journal of Cancer 2013, in press
IF 5,04 CI nd
A2.
S. Luminari, I. Biasoli, L. Arcaini, A. Versari, C. Rusconi, F. Merli, M. Spina, A. J.
M. Ferreri, P. L. Zinzani, A. Gallamini, S. Mastronardi, C. Boccomini, G. Gaidano,
A. M. D’Arco, F. di Raimondo, A. M. Carella, A. Santoro, P. Musto, M. Federico:
The use of FDG-PET in the initial staging of 142 patients with follicular
lymphoma: a retrospective study from the FOLL05 randomized trial of the
Fondazione Italiana Linfomi.
Annals of Oncology 00:1-5,2013
IF 6,42 CI nd
A3.
G. Gullo, D. Bettio, M. Zuradelli, G. Masci, L. Giordano, C. Bareggi, M.
Tomirotti, P. Salvini, L. Runza, N. La Verde, Santoro A.: Level of HER2/neu
amplification in primary tumours and metastases in HER2-positive breast cancer
and survival after trastuzumab therapy.
The Breast 22: 190-193, 2013 IF 2.49 CI nd
A4.
N. Personeni, L. Rimassa, T. Pressiani, A. Destro, C. Ligorio, M.C. Tronconi, S.
Bozzarelli, C. Carnaghi, L. di Tommaso, L. Giordano, M. Roncalli, A. Santoro:
Molecular determinants of out come in sorafenib-treated patients with
hepatocellular carcinoma.
J
Cancer
Res
Clin
Oncol
139:1179-1187,2013
IF 2.55 CI nd
A5.
T. Pressiani, C. Boni, L. Rimassa, R. Labianca, S. Fagiuoli, S. Salvagni, D.
Ferrari, E. Cortesi, C. Porta, C. Mucciarini, L. Latini, C. Carnaghi, M. Banzi, S.
Fanello, M. De Giorgio, F. R. Lutman, G. Torzilli, M. A. Tommasini, R. Ceriani, G.
Covini, M. C. Tronconi, L. Giordano, N. Locopo, S. Naimo, A. Santoro: Sorafenib
in patients with Child-Plugh class a and B advanced hepatocellular carcinoma: a
prospective feasibility analysis.
Annals of Oncology 24(2):406-11,2013
IF 6,42 CI nd
A6.
L. Rimassa, N. Personeni, M. Simonelli, A. Santoro: Tivantinib: a new
promising mesenchymal-epithelial transition factor inhibitor in the treatment of
hepatocellular carcinoma.
Future Oncology Feb;9(2):153-65, 2013
IF 3.16 CI nd
A7.
L. Rimassa, T. Pressiani, C. Boni, C. Carnaghi, E. Rota Caremoli, S. Fagiuoli, P.
Foa, S. Salvagni, E. Cortesi, M.C. Tronconi, N. Personeni, S. Bozzarelli, M.C.
Banzi, S. Fanello, F. R. Lutman, L. Giordano, A. Santoro: A phase II randomized
dose escalation trial of Sorafenib in patients with advanced hepatocellular
carcinoma.
The
Oncologist
18;379-380,2013
IF 3.91CI nd
A8.
P. Rougier, H. Riess, R. Manges, P. Karasek, Y. Humblet, C. Carone, A.
Santoro, S. Assadouriann, L. Hatteville, P. A. Phillip: Randomized, placebocontrolled, double-bind, parallel-group phase III study evaluating aflibercept in
patients receiving first-line treatment with gemcitabine for metastatic pancreatic
cancer.P. R
European
Journal
of
Cancer,2013
IF 5.53 CI nd
A9.
A. Santoro, A. Comandone, U. Basso, H. Soto Parra, R. De Sanctis, E. Stroppa,
I. Marcon, L. Giordano, F. R. Lutman, A. Boglione, A. Bertuzzi: Phase II
prospective study with sorafenib in advanced soft tissue sarcomas after
anthracycline-based therapy.
Annals of Oncology 24: 1093–1098, 2013.
IF 6,42 CI nd
A10.
A. Santoro L. Rimassa, I. Borbath, B. Daniele, S. Salvagni, J.L. Van Laethem, H.
Van Vlierberghe,
J. Trojan, F.T. Kolligs, A. Weiss, S. Miles, A. Gasbarrini, M. Lencioni, L. Cicalese,
M. Sherman, C.
Gridelli, P. Buggisch, G. Gerken, R. M. Schmid, C. Boni, N. Personeni, Z. Hassoun,
G. Abbadessa,
B. Schwartz, R. Von Roemeling, M. E. Lamar, Y. Chen, C. Porta: Tivantinib for
second-line treatment of advanced hepatocellular carcinoma: a randomized,
placebo-controlled phase 2 study.
Lancet Oncology 14(1):55-63,2013
IF 22,58 CI 03
2
A11.
A. Santoro, M. Simonelli, C. Rodriguez-Lope, P. Zucali, L. H.
Granito, N. Senzer, L. Rimassa, G. Abbadessa, B. Schwarz, M.
Savage, J. Bruix: A Phase-1B study of tivantinib (ARQ 197) in adult
hepatocellular carcinoma and cirrosi.
British
Journal
of
Cancer
108(1):
IF 5,04 CI 02
Camacho, A.
Lamar, R. E.
patients with
21-24,2013
A12.
F. Sclafani, M. Incarbone, L. Rimassa, N. Personeni, L. Giordano, M. Alloisio, A.
Santoro: The role of hepatic metastases and pulmonary tumor burden in
predicting survival after complete pulmonary resection for colorectal cancer.
The Journal of Thoracic and Cardiovascular Surgery 145(1):97-103,2013
IF 3.40 CI nd
A13.
M. Simonelli, P.A. Zucali, R. De Sanctis, E. Lorenzi, F. de Vincenzo, L. Rimassa,
M.C. Tronconi, M. Zuradelli, L. Giordano, A. Santoro: Phase I, Pharmacokinetics,
Pharmacodynamic, study of lapatinib in combination with sorafenib in patients
with advanced refractpry solid tumors.
European
Journal
of
Cancer
49(5):989-998,2013
IF 5.53 CI nd
A14.
E. Todisco, F. Ciceri, E. Oldani, C. Boschini, C. Mice, M.T. VanLint, I. Donnini,
F. Patriarca, P.E. Alessandrino, F. Bonifazi, W. Arcese, W. Barberi, P. MArenco, E.
Terruzzi, S. Cortellazzo, S. Santarone, A. Proia, P. Corradini, E. Tagliaferri, S.
Falcioni, G. Irrera, L. Dallanegra, L. Castagna, A. Santoro, A. CAmboni, N. Sacchi,
A. Bosi, A. Bacigalupo, A. Rambaldi: The CIBMTR score predicts of AML patients
undergoing allogeneic transplantation with active disease after a myeloablative
or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano
Trapianto Midollo Osseo (GITMO).
Leukemia
DOI:
10.1038/leu.2013.208
IF 10.16 CI nd
A15.
R. Torrisi, C.A. Garcia-Etienne, A. Losurdo, E. Morenghi, L. Di Tommaso, W.
Gatzemeier,A. Sagona, B. Fernandes, C. Rossetti, M. Eboli, A. Rubino, E. Barbieri,
C. Andreoli, S. Orefice,
C. Gandini, S. Rota, M. Zuradelli, G. Masci, A.
Santoro, C. Tinterri: Potential impact of the 70-gene signature in the choice of
adjuvant systemic treatment for ER positive, HER2 negative tumors: A single
institution experience.
The
Breast
3:
1-6,2013
IF 2.49 CI nd
TçLKçLKçLKçLKçLKçLKçLK
3
A16.
P. Tralongo, M.A. Annunziata, A. Santoro, U.Tirelli, A. Surbone: Beyond semantic: the
need to better categorie patients with cancer.
Journal of Clinical OncologyJ2013 (in press)
IF
18.37 CI nd
A17.
P. Zinzani, S. Viviani, A. Anastasia, U. Vitolo, S. Luminari, F. Zaja, P. Corradini,
M. Spina, E. Brusamolino, A. M. Gianni, A. Santoro, B. Botto, E. Derenzini, C.
Pellegrini, L. Argnani: Brentuximab vedotin in relapsed/refractory Hodgkin’s
lymphoma: Italian experience and results of the use in the daily clinic outside
clinicl trials.
Haematologica
2013
(in
press)
IF 6,42 CI nd
A18.
GP. Zucali, L. di Tommaso, I. Petrini, S. Battista, H.S. Lee, M. Merino, E. Lorenzi,
l og
Tralongo,sshj
E. Voulaz, F. De Vincenzo, M. SImonelli, M. Roncalli, L. Giordano, M. Alloisio, A.
Santoro, G. Giaccone: Reproducibility of the WHO classification of thymomas:
practical implications.
Lung
Cancer
79(3):236-241,2013
IF 3.43 CI nd
A19.
P. A. Zucali, M. Simonelli, F. De Vincenzo, E. Lorenzi, M. Perrino, M. Bertossi,
R. Finotto, S. Naimo, L. Balzarini, C. Bonifacio, I. Timofeeva, G. Rossoni, G.
Mazzola, A. Lambiase, C. Bordignon, A. Santoro: Phase I and pharmacodynamic
study of high-dose NGR-hTNF in patients with refractory solid tumours.
British Journal of Cancer 49:989-998,2013
4